Keros Therapeutics is a clinical-stage biopharmaceutical organization dedicated to the discovery, development, and commercialization of novel protein therapeutics directed at the transforming growth factor-beta signaling pathway. The company leverages its proprietary protein-engineering platform to design and build targeted medicines that address severe and rare diseases across multiple therapeutic areas, including hematologic, pulmonary, and cardiovascular disorders. By modulating specific protein interactions that govern tissue repair, blood cell production, and muscle growth, Keros aims to deliver innovative treatment options for patients who currently face limited medical alternatives.